Qi, Weijie
Ooi, Andrew
Grayden, David B.
Opie, Nicholas L.
John, Sam E.
Funding for this research was provided by:
China Scholarship Council (202008240002)
Congressionally Directed Medical Research Programs (EP170058, EP170058, EP170058)
National Health and Medical Research Council (1158912, 1158912, 1158912)
Article History
Received: 10 May 2023
Accepted: 18 March 2024
First Online: 27 March 2024
Competing interests
: NLO is a director and holds stock options in Synchron Inc. DBG, NLO and SEJ have patents related to the Stentrode technology. Other authors do not have any competing interests.